Business Description
VYNE Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US5868581027
Description
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 435.76 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -7.49 | |||||
| Beneish M-Score | -3.79 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -84.8 | |||||
| 3-Year EBITDA Growth Rate | 72.7 | |||||
| 3-Year EPS without NRI Growth Rate | 65.2 | |||||
| 3-Year FCF Growth Rate | 68.1 | |||||
| 3-Year Book Growth Rate | -26.1 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.46 | |||||
| 9-Day RSI | 37.63 | |||||
| 14-Day RSI | 43.67 | |||||
| 6-1 Month Momentum % | -29.97 | |||||
| 12-1 Month Momentum % | -31.4 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 12.73 | |||||
| Quick Ratio | 12.73 | |||||
| Cash Ratio | 12.37 | |||||
| Days Sales Outstanding | 212.29 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -80.4 | |||||
| Shareholder Yield % | -0.87 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -6900.71 | |||||
| Net Margin % | -6710.38 | |||||
| FCF Margin % | -5976.65 | |||||
| ROE % | -81.22 | |||||
| ROA % | -65.28 | |||||
| ROIC % | -823.13 | |||||
| ROC (Joel Greenblatt) % | -14134.78 | |||||
| ROCE % | -80.96 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 21.24 | |||||
| PB Ratio | 0.36 | |||||
| Price-to-Tangible-Book | 0.36 | |||||
| EV-to-EBIT | 2.02 | |||||
| EV-to-Forward-EBIT | -0.1 | |||||
| EV-to-EBITDA | 2.02 | |||||
| EV-to-Forward-EBITDA | -0.1 | |||||
| EV-to-Revenue | -139.63 | |||||
| EV-to-Forward-Revenue | 0.19 | |||||
| EV-to-FCF | 2.34 | |||||
| Price-to-Net-Current-Asset-Value | 0.36 | |||||
| Price-to-Net-Cash | 0.38 | |||||
| Earnings Yield (Greenblatt) % | 49.5 | |||||
| FCF Yield % | -79.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:VYNE
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
VYNE Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.424 | ||
| EPS (TTM) ($) | -7.279 | ||
| Beta | 2.3 | ||
| Volatility % | 110.83 | ||
| 14-Day RSI | 43.67 | ||
| 14-Day ATR ($) | 0.245463 | ||
| 20-Day SMA ($) | 2.7235 | ||
| 12-1 Month Momentum % | -31.4 | ||
| 52-Week Range ($) | 1.67 - 8.73 | ||
| Shares Outstanding (Mil) | 14.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
VYNE Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
VYNE Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
VYNE Therapeutics Inc Frequently Asked Questions
What is VYNE Therapeutics Inc(VYNE)'s stock price today?
The current price of VYNE is $2.25. The 52 week high of VYNE is $8.73 and 52 week low is $1.67.
When is next earnings date of VYNE Therapeutics Inc(VYNE)?
The next earnings date of VYNE Therapeutics Inc(VYNE) is 2024-05-10 Est..
Does VYNE Therapeutics Inc(VYNE) pay dividends? If so, how much?
VYNE Therapeutics Inc(VYNE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers